Related Experiment Video
Updated: Oct 25, 2025
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Angiogenesis pattern and H3.3 histone mutation in aggressive and non-aggressive central giant cell lesions
Sérgio Alves de Oliveira Filho1, Allisson Filipe Lopes Martins2, Carla Mosconi2
1Department of Stomathology (Oral Pathology), Faculdade de Odontologia da Universidade Federal de Goiás, GO, Brazil.
Objective:
The aim of this study was to evaluate angiogenesis in central giant cell lesions (CGCL) and its association with biological behavior. In addition, investigation of the histone H3.3 mutation was performed.
Design:
Thirty-eight cases of CGCL were classified as aggressive (n = 9) or nonaggressive (n = 29). Cases were submitted to immunohistochemistry to compare angiogenesis using Wilms' tumor protein 1 (WT1), platelet endothelial cell adhesion molecule (CD31) and endoglin (CD105) between groups. To verify the presence of genic mutation, histone H3.3 was investigated.
Results:
WT1 was expressed in mononuclear and giant cells of all cases. CD31 and CD105 were expressed in CGCL microvessels, with a higher CD105 microvascular density than CD31. No statistically significant difference was observed between groups. None of the cases studied showed the histone mutation.
Conclusions:
There was no difference between aggressive and nonaggressive lesions regarding the angiogenic markers. The expression of WT1 and CD105 suggests that CGCL presents a tumoral vascular pattern with high neoangiogenic activity. The absence of histone mutation may indicate that CGCL is not a true giant cell tumor.
Related Concept Videos
02:30Histone Variants at the Centromere
02:23Abnormal Proliferation